{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:12:22Z","timestamp":1791414742350,"version":"4.3.3"},"reference-count":90,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,1,24]],"date-time":"2005-01-24T00:00:00Z","timestamp":1106524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Birth Defects Research"],"published-print":{"date-parts":[[2005,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Angiotensin II (A\u2010II) is the main effector of the renin\u2010angiotensin system. A\u2010II functions by binding its type 1 (AT1) receptors to cause vasoconstriction and retention of sodium and fluid. Several AT1 receptor antagonists\u2014a group of drugs collectively called \u201csartans\u201d\u2014have been marketed during the past few years for treatment of hypertension and heart failure. At least 15 case reports describe oligohydramnios, fetal growth retardation, pulmonary hypoplasia, limb contractures, and calvarial hypoplasia in various combinations in association with maternal losartan, candesartan, valsartan, or telmisartan treatment during the second or third trimester of pregnancy. Stillbirth or neonatal death is frequent in these reports, and surviving infants may exhibit renal damage. The fetal abnormalities, which are strikingly similar to those produced by maternal treatment with angiotensin\u2010converting enzyme (ACE) inhibitors during the second and third trimesters of pregnancy, are probably related to extreme sensitivity of the fetus to the hypotensive action of these drugs. Very little information is available regarding the outcome of human pregnancies in which the mother was treated with an AT1 receptor antagonist during the first trimester, but animal studies have not demonstrated teratogenic effects after maternal treatment with large doses of AT1 receptor antagonists during organogenesis. We conclude that pharmacological suppression of the fetal renin\u2010angiotensin system through ACE inhibition or AT1 receptor blockade seems to disrupt fetal vascular perfusion and renal function. We recommend that maternal treatment with AT1 receptor antagonists be avoided during the second and third trimesters of pregnancy and that women who become pregnant while taking one of these medications be changed to an antihypertensive drug of a different class as soon as the pregnancy is recognized. Birth Defects Research (Part A) 73, 2004. \u00a9 2004 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/bdra.20102","type":"journal-article","created":{"date-parts":[[2005,1,24]],"date-time":"2005-01-24T16:47:21Z","timestamp":1106585241000},"page":"123-130","source":"Crossref","is-referenced-by-count":156,"title":["Angiotensin II receptor antagonist treatment during pregnancy"],"prefix":"10.1002","volume":"73","author":[{"given":"S.","family":"Alwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.E.","family":"Polifka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,1,24]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"2626","article-title":"Valsartan. Just a second\u2010line antihypertensive drug","volume":"45","year":"1999","journal-title":"Can Fam Physician"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420440503"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420500606"},{"key":"e_1_2_6_5_1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1001\/archinte.1995.00430130027004","article-title":"The angiotensin II type I receptor\u2010antagonists, a new class of antihypertensive drugs","volume":"155","author":"Bauer JH","year":"1995","journal-title":"Arch Intern Med"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-199917070-00002"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001490"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420430602"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A013"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80066-8"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006822911586"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jp.7211011"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8628(19991029)86:5<430::AID-AJMG7>3.0.CO;2-J"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04759-0"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.2003.02139.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464090-00011"},{"key":"e_1_2_6_17_1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/ajhp\/57.13.1231","article-title":"Angiotensin II\u2010receptor antagonists: an overview","volume":"57","author":"Dina R","year":"2000","journal-title":"Am J Health Syst Pharm"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.3.11.1543"},{"key":"e_1_2_6_19_1","first-page":"S1","article-title":"Molecular biology of angiotensin receptors: target for drug research?","volume":"12","author":"Dzau VJ","year":"1994","journal-title":"J Hypertens"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1006\/jmcc.1996.0259"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1113\/expphysiol.1997.sp004063"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1994.63"},{"key":"e_1_2_6_23_1","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1742-1241.2003.tb10631.x","article-title":"The adjunctive effect of telmisartan in patients with hypertension uncontrolled on current antihypertensive therapy","volume":"57","author":"Gil\u2010Extremera B","year":"2003","journal-title":"Int J Clin Pract"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199651050-00008"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00852571"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001434"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115395"},{"issue":"2","key":"e_1_2_6_28_1","first-page":"F326","article-title":"Autoradiographic characterization of angiotensin receptor subtypes in fetal and adult human kidney","volume":"262","author":"Grone HJ","year":"1992","journal-title":"Am J Physiol"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200018020-00001"},{"key":"e_1_2_6_30_1","first-page":"128","article-title":"Fetal and neonatal effects of treatment with angiotensin\u2010converting enzyme inhibitors in pregnancy","volume":"78","author":"Hanssens M","year":"1991","journal-title":"Obstet Gynecol"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)10327-1"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04758-9"},{"key":"e_1_2_6_33_1","first-page":"4043","article-title":"Toxicity studies of losartan potassium, angiotensin II receptor antagonist (5th report)\u2014Oral developmental toxicity study in rabbits","volume":"28","author":"Hiroyoshi M","year":"1994","journal-title":"Kiso to Rinsho"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.32.3.387"},{"key":"e_1_2_6_35_1","first-page":"914","article-title":"Angiotensin receptor antagonists and ACE inhibitors","volume":"27","author":"Howes LG","year":"1998","journal-title":"Aust Fam Physician"},{"key":"e_1_2_6_36_1","first-page":"673","article-title":"Angiotensin\u2010converting enzyme inhibitors in pregnancy may result in neonatal renal failure","volume":"78","author":"Hulton SA","year":"1990","journal-title":"S Afr Med J"},{"key":"e_1_2_6_37_1","first-page":"S2","article-title":"Molecular biology and singalling of angiotensin receptors: an overview","volume":"10","author":"Inagami T","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/109158199225071"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardiores.2004.01.011"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1053\/ob.1996.v175.a74409"},{"key":"e_1_2_6_41_1","first-page":"11","article-title":"Molecular and cellular mechanisms of angiotensin II\u2010mediated cardiovascular and renal diseases","volume":"52","author":"Kim S","year":"2000","journal-title":"Pharmacol Rev"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.7.2735"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04757-7"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(99)00111-X"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0705.2000.00228.x"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1159\/000190179"},{"key":"e_1_2_6_47_1","first-page":"25","article-title":"Contribution of kinins to the cardiovascular actions of angiotensin\u2010converting enzyme inhibitors","volume":"47","author":"Linz W","year":"1995","journal-title":"Pharmacol Rev"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/0009-9236(95)90020-9"},{"key":"e_1_2_6_49_1","first-page":"649","article-title":"Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding","volume":"295","author":"Maillard MP","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1000880"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199754020-00009"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420460402"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05426-5"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199604113341502"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0146-0005(97)80055-9"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199855050-00011"},{"key":"e_1_2_6_57_1","volume-title":"The developing human: clinically oriented embryology","author":"Moore KL","year":"2003"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02730601"},{"key":"e_1_2_6_59_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118366"},{"issue":"2","key":"e_1_2_6_60_1","first-page":"S9","article-title":"Candesartan cilexetil: a review of its preclinical pharmacology","volume":"11","author":"Nishikawa K","year":"1997","journal-title":"J Hum Hypertens"},{"issue":"2","key":"e_1_2_6_61_1","first-page":"R662","article-title":"Differential expression of angiotensin II receptors during early renal morphogenesis","volume":"272","author":"Norwood VF","year":"1997","journal-title":"Am J Physiol"},{"key":"e_1_2_6_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199209033271001"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jp.7210871"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00807-8"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(97)00386-5"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1006\/dbio.1997.8764"},{"key":"e_1_2_6_67_1","first-page":"1047","article-title":"Taking ACE inhibitors during pregnancy. Is it safe?","volume":"48","author":"Ratnapalan S","year":"2002","journal-title":"Can Fam Physician"},{"key":"e_1_2_6_68_1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/ajhp\/58.8.671","article-title":"Angiotensin II\u2010receptor blockers: clinical relevance and therapeutic role","volume":"58","author":"Rodgers JE","year":"2001","journal-title":"Am J Health Syst Pharm"},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(90)90818-R"},{"key":"e_1_2_6_70_1","first-page":"S15","article-title":"Human pharmacokinetic\/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist","volume":"15","author":"Ruilope L","year":"1997","journal-title":"J Hypertens"},{"key":"e_1_2_6_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03648-5"},{"key":"e_1_2_6_72_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002809603000611"},{"key":"e_1_2_6_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.10081"},{"key":"e_1_2_6_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/00041552-200401000-00016"},{"key":"e_1_2_6_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90172-4"},{"key":"e_1_2_6_76_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006250-200208000-00029"},{"key":"e_1_2_6_77_1","doi-asserted-by":"publisher","DOI":"10.1097\/00041552-199401000-00016"},{"key":"e_1_2_6_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420510603"},{"key":"e_1_2_6_79_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420510604"},{"key":"e_1_2_6_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9926(199604)53:4<245::AID-TERA7>3.0.CO;2-1"},{"key":"e_1_2_6_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1681.1996.tb02583.x"},{"key":"e_1_2_6_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(74)80753-5"},{"key":"e_1_2_6_83_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116232"},{"key":"e_1_2_6_84_1","first-page":"F110","article-title":"Angiotensin II regulates nephrogenesis and renal vascular development","volume":"269","author":"Tufro\u2010McReddie A","year":"1995","journal-title":"Am J Physiol"},{"key":"e_1_2_6_85_1","volume-title":"USP DI (USP dispensing information)","author":"USP DI","year":"2004"},{"key":"e_1_2_6_86_1","volume-title":"USP DI (USP dispensing information)","author":"USP DI","year":"2004"},{"key":"e_1_2_6_87_1","volume-title":"USP DI (USP dispensing information)","author":"USP DI","year":"2004"},{"key":"e_1_2_6_88_1","volume-title":"USP DI (USP dispensing information)","author":"USP DI","year":"2004"},{"key":"e_1_2_6_89_1","volume-title":"USP DI (USP dispensing information)","author":"USP DI","year":"2004"},{"key":"e_1_2_6_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1084-2756(03)00022-8"},{"key":"e_1_2_6_91_1","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJM198812083192305","article-title":"Converting\u2010enzyme inhibitors in the treatment of hypertension","volume":"319","author":"Williams GH","year":"1988","journal-title":"N Engl J Med"}],"container-title":["Birth Defects Research Part A: Clinical and Molecular Teratology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdra.20102","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdra.20102","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T23:44:40Z","timestamp":1697499880000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdra.20102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,24]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["10.1002\/bdra.20102"],"URL":"https:\/\/doi.org\/10.1002\/bdra.20102","archive":["Portico"],"relation":{},"ISSN":["1542-0752","1542-0760"],"issn-type":[{"value":"1542-0752","type":"print"},{"value":"1542-0760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,24]]}}}